Roche's Perjeta get another EU approval; CSL ready to buy Novartis vaccines; EU docs distrust pharma-made apps;

@FiercePharma: IDEXX shares climb on record diagnostics placements and Q2 earnings gain. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: As Hospira expands recall of ketorolac to 37M vials you've got to wonder what Pfizer thinks. Story | Follow @EricPFierce

@CarlyHFierce: Celgene fights for sanction on patent challenger Bass. More | Follow @CarlyHFierce

> Roche's ($RHHBY) Perjeta has won a new indication in Europe for use with Herceptin before surgery in HER2-postive breast cancer patients. Story

> A new survey of general practitioners in three European countries found that they distrust mobile apps made by drugmakers. Report

> Australia's CSL says it has the approvals to complete its buyout of Novartis ($NVS) influenza vaccine business and is working with the Swiss drugmaker to complete the deal. Story

> The FDA is warning doctors and pharmacies to be careful not to confuse Brintellix, an antidepressant, with Brilinta, a blood-thinning medication. Report

Medical Device News

@FierceMedDev: FierceDiagnostics story: Foundation Medicine trips in Q2 with sluggish test reimbursement. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: NeuWave Medical gets FDA clearance for software upgrade to its ablation system. Report | Follow @VarunSaxena2

@EmilyWFierce: It's not a good week to be a drugmaker in Romania. More from FiercePharma | Follow @EmilyWFierce

> Upstart gets $6M to back the first FDA-cleared, OTC conception assistance device. Story

> Lombard Medical gains a second stent graft for aneurysm repair via $50M acquisition. Article

> CMS expands Medicare coverage of speech-generating devices. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Failed Alzheimer's drug wins $117M in vTv's IPO. Article | Follow @FierceBiotech

@JohnCFierce: 125 ex-$GSK R&D staffers in RTP face the ax--again (Great industry. Where else can you get fired twice in 8 months?) News | Follow @JohnCFierce

> Amgen lops another 10% off its R&D budget amid wide cost cuts. Story

> Merck's Ebola vaccine is 100% successful in interim Phase III results. News

> AstraZeneca isn't giving up on brodalumab despite its links to suicide. Article